2026-04-14T03:07:32Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1737592025-12-05T12:07:26Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Roger, Albert author Malet, Alfons author Moreno, Victoria author Parra, Antonio author Gutierrez, Diego author Lleonart Bellfill, Ramon author Moreno, Francisco author Valero, Antonio author Navarro, Begoña author Hinojosa, Belén author Justicia, José L. author 2021-02-09T09:36:19Z 2021-02-09T09:36:19Z 2020-01-01 2021-02-08T10:12:28Z Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting. Àcars Rinitis Mites Rhinitis Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis